ADAM17 and neoplasm: To demonstrate that ADAM17 deficiency in cardiomyocytes does not affect the efficacy of doxorubicin in suppressing tumor growth, we used breast cancer cells E0771 to establish tumor models in A17fl/fl and A17α-MHCKO female mice, who were treated with normal saline or doxorubicin once a week for 4 weeks after E0771 injection (Fig. 8a).